Metastasis News and Research RSS Feed - Metastasis News and Research

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases
Gene in brain promotes kidney cancer, report researchers

Gene in brain promotes kidney cancer, report researchers

A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. [More]
New concept of organs on a chip may help study cancer metastasis

New concept of organs on a chip may help study cancer metastasis

The recent development of the concept of organs on a chip opens the possibility of realistically studying human organs without the use of patients or animal testing. [More]
Overlooked DNA shuffling drives deadly paediatric brain tumour

Overlooked DNA shuffling drives deadly paediatric brain tumour

One of the deadliest forms of paediatric brain tumour, Group 3 medulloblastoma, is linked to a variety of large-scale DNA rearrangements which all have the same overall effect on specific genes located on different chromosomes. [More]
FAK inhibitors prevent ovarian cancer progression

FAK inhibitors prevent ovarian cancer progression

A team of scientists, led by principal investigator David D. Schlaepfer, PhD, professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine report that small molecule inhibitors to a protein called focal adhesion kinase (FAK) selectively prevent the growth of ovarian cancer cells as tumor spheroids. [More]
Researchers explore how neurons establish spatial polarity and direction in tissues, organs

Researchers explore how neurons establish spatial polarity and direction in tissues, organs

The question of how neurons and their axons establish spatial polarity and direction in tissues and organs is a fundamental question of any organism or biological system. [More]
NIH receives $10 million grant for research on breast cancer metastasis

NIH receives $10 million grant for research on breast cancer metastasis

The American Cancer Society predicts that 40,000 American women will die from breast cancer this year. Most of those deaths will occur due to cells from the primary tumor that spread to other parts of the body-the process known as metastasis. [More]
Yap1 oncogene drives recurrence and progression of pancreatic cancer

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell. [More]
Wistar findings suggest means of boosting initial immune response

Wistar findings suggest means of boosting initial immune response

Your first response to an infectious agent or antigen ordinarily takes about a week, and is relatively weak. However, if your immune system encounters that antigen a second time, the so-called memory response is rapid, powerful, and very effective. [More]
Combination of novel molecular imaging techniques can help predict spread of cancer, patient survival

Combination of novel molecular imaging techniques can help predict spread of cancer, patient survival

A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients' chances of survival, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. [More]
Scientists identify new way to reactivate latent HIV

Scientists identify new way to reactivate latent HIV

A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself, which could help overcome one of the biggest obstacles to finding a cure for HIV infection. [More]
New book documents groundbreaking studies on modified citrus pectin

New book documents groundbreaking studies on modified citrus pectin

One of the nation's leading writers on the use of naturopathic medicine has released a new book documenting groundbreaking studies on modified citrus pectin (MCP) and its application for addressing serious health issues like cancer, heart disease, chronic inflammation and fibrosis. [More]
Cornell researchers take new approach to screening aggressive cancer cells

Cornell researchers take new approach to screening aggressive cancer cells

Not all cancer cells are created equal - some stay put in the primary tumor, while others move and invade elsewhere. A major goal for cancer research is predicting which cells will metastasize, and why. [More]
Scientist discovers new path to stop breast cancer cells from invading organs

Scientist discovers new path to stop breast cancer cells from invading organs

The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine- scientists have discovered a new pathway that can stop breast cancer cells from spreading. [More]
Ezyme used as target for antidepressants may also provide way to cure prostate cancer

Ezyme used as target for antidepressants may also provide way to cure prostate cancer

An international team of scientists including researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and the University of Southern California found that an enzyme commonly used as a target for antidepressants may also promote prostate cancer growth. [More]
Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). [More]
New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014. [More]
FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM). [More]
Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701). [More]
Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients. [More]
Women with metastatic breast cancer can receive bisphosphonates less frequently and safely

Women with metastatic breast cancer can receive bisphosphonates less frequently and safely

Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. [More]